Point72 Asset Management
TNXP icon

Point72 Asset Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Point72 Asset Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72M Sell
125,414
-494,619
-80% -$7.61M ﹤0.01% 2419
2025
Q4 		$9.68M Buy
+620,033
New +$11.4M 0.01% 1376
2025
Q1 		– Sell
-15,963
Closed -$526K – 2538
2024
Q4 		$526K Buy
+15,963
New +$332K ﹤0.01% 1653

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Point72 Asset Management's TNXP Position: Q1 2026 in Review

Point72 Asset Management reduced its Tonix Pharmaceuticals (TNXP) stake by 80% in Q1 2026, selling an estimated $7.61M and leaving 125,414 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2419.

Point72 Asset Management first reported a position in TNXP in Q4 2024 and has held it in 3 quarters since. The position peaked at $9.68M in Q4 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Point72 Asset Management held 125,414 shares of Tonix Pharmaceuticals worth $1.72M as of Q1 2026.
  • Point72 Asset Management sold 494,619 Tonix Pharmaceuticals shares in Q1 2026, an estimated $7.61M.
  • Tonix Pharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2419 holding.
  • Point72 Asset Management first reported a position in Tonix Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • Point72 Asset Management's Tonix Pharmaceuticals position peaked at $9.68M in Q4 2025.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.